

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	9403175
<b>Application Number:</b>	10534348
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4929
<b>Title of Invention:</b>	Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
<b>First Named Inventor/Applicant Name:</b>	Karen Silence
<b>Customer Number:</b>	23628
<b>Filer:</b>	Erik J. Spek/Eileen Flaherty
<b>Filer Authorized By:</b>	Erik J. Spek
<b>Attorney Docket Number:</b>	A0848.70005US00
<b>Receipt Date:</b>	08-FEB-2011
<b>Filing Date:</b>	09-MAY-2005
<b>Time Stamp:</b>	19:26:39
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Reiter_et_al_NatBiotechnol_1996_v14_p1239.pdf	1536056 9bd5a078ac2ae29231e8f26eb593834a2177695a	no	7

### Warnings:

### Information:

2	NPL Documents	Reiter_et_al_JMolBiol_1999_v290_p685.pdf	332392	no	14
			53c2458c841146d3a3eb3396f613e413a85cdc87		
Warnings:					
Information:					
3	NPL Documents	Rheinnecker_et_al_JImmunol_1996_v157_p2989.pdf	1006138	no	9
			0b2e749343a87fac3b85195e4917c62d51465619		
Warnings:					
Information:					
4	NPL Documents	Riechmann_et_al_J_Immunol_Meth_1999_v231_p25.pdf	1158522	no	15
			980cb09e11170a76175f07595905a177d11bf5dd		
Warnings:					
Information:					
5	NPL Documents	Riemer_et_al_MollImmunol_2005_v42_p1121.pdf	638216	no	4
			d424ac61b77555b7b01ed516bc679dfc6e424fe5		
Warnings:					
Information:					
6	NPL Documents	Roovers_et_al_CanclImmunol_2007_v56_p303.pdf	554887	no	15
			d4e579fa10514ffe85c22bfe464c861d1306718f		
Warnings:					
Information:					
7	NPL Documents	Rosenberg_AAPSJournal_2006_v8_pE501.pdf	167563	no	7
			78f4c51bc05e58a7cb06a0d668e9a93fbaa13df9		
Warnings:					
Information:					
8	NPL Documents	Saerens_et_al_JMolBiol_2005_v352_p597.pdf	1147766	no	11
			45d1124e1dd04117c4c4e2385793167879d92691		
Warnings:					
Information:					
9	NPL Documents	Scheurich_et_al_IntJCancer_1986_v38_p127.pdf	567969	no	7
			da97cab78088f69874b956c3bb267ed2bca9b0f9		
Warnings:					
Information:					
10	NPL Documents	Schlaeppli_et_al_JCancerResClinOncol_1999_v125_p336.pdf	675930	no	7
			5621fe87893f6190800063f00a588f2a0634665e		
Warnings:					
Information:					

11	NPL Documents	Silacci_et_al_Proteomics_2005_v5_p2340.pdf	1498482	no	11
			f72f302b481db51f05689501e19bb2948a7898c		
Warnings:					
Information:					
12	NPL Documents	Smith_et_al_Bioconjugate_Chem_2001_v12_p750.pdf	743990	no	8
			114238d9a2dd3e68815c20158822e4c75edd4b56		
Warnings:					
Information:					
13	NPL Documents	Stahl_et_al_PatholBiol_1997_v45_p66.pdf	1283074	no	11
			a74c8720a108aa1672cb6be686131902f5bf2d56		
Warnings:					
Information:					
14	NPL Documents	Stancovski_et_al_PNAS_1991_v88_p8691.pdf	1178830	no	5
			e7bac079a6d74350cf99c8f6f0b4fc758d00a65f		
Warnings:					
Information:					
15	NPL Documents	Tersikh_et_al_PNAS_1997_v94_p1663.pdf	860371	no	6
			eee2c181e47303bf5c62bccee28b620f09e3b5f0		
Warnings:					
Information:					
16	NPL Documents	Tijink_et_al_MolCancerTher_2008_v7_p2288.pdf	1081552	no	10
			05a1f83be238b1c9404f8f8dc73d749c11d5ba5d7		
Warnings:					
Information:					
17	NPL Documents	van_den_Beucken_JMolBiol_2001_v310_p591.pdf	605179	no	12
			7959212014a10e1d4fd9d4639617fcfb379ba5db2		
Warnings:					
Information:					
18	NPL Documents	Van_Der_Linden_et_al_J_Immunol_Methods_2000_v240_p185.pdf	1059670	no	11
			1f31b9089c2c2c88b4d0e7f8eaf2f0eee7137034		
Warnings:					
Information:					
19	NPL Documents	Vickers_DrugsAging_2002_v19_p487.pdf	1518765	no	8
			0cd198f7c77097b2c0b1ca83eda4346f184942ac		
Warnings:					
Information:					

20	NPL Documents	VanderVaartetalVaccine2006v24p4130.pdf	705638	no	8
			f2ae45dd49f42a2c4adc1ef27d1da630b9cfb6bc		
Warnings:					
Information:					
21	NPL Documents	Waldmann_et_al_JClinInvest_1972_v51_p2162.pdf	2508524	no	13
			9f089ae9cb048dd3351fc48ab54f6d4a0dfbcb13		
Warnings:					
Information:					
22	NPL Documents	Wesolowski_et_al_MedMicrobiolImmunol_2009_v198_p157.pdf	906381	no	18
			0b27b2448c489f4ba42e962b760dddcb5fc88f5		
Warnings:					
Information:					
23	NPL Documents	Winkler_et_al_J_Immunol_2000_v165_p4505.pdf	3090929	no	10
			9b9739604ee29c163334876318527926faaf3b4f		
Warnings:					
Information:					
24	NPL Documents	Witte_et_al_Cancer_Metast_Review_1998_v17_p155.pdf	689011	no	7
			5d857a6a97920151ebe30150554ed7ecd0c662ba		
Warnings:					
Information:					
25	NPL Documents	Zhu_et_al_InvestNewDrugs_1999_v17_p195.pdf	1455093	no	18
			3b2b9e13372d0151d15befd36fea813cddcf6391		
Warnings:					
Information:					
Total Files Size (in bytes):			26970928		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**